Cargando…

Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway

INTRODUCTION: Temozolomide (TMZ) induces intestinal mucosa injury that cannot be fully counteracted by supportive treatment. Probiotics regulate gut microbial composition and the host immune system and may alleviate this side effect. We aimed to investigate the potential and mechanism of Lactobacill...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaochong, Hu, Bowen, Zheng, Jiachen, Pan, Zhiyong, Cai, Yuxiang, Zhao, Mingjuan, Jin, Xiaoqing, Li, Zhi-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386857/
https://www.ncbi.nlm.nih.gov/pubmed/37521036
http://dx.doi.org/10.2147/DDDT.S403087
_version_ 1785081768951414784
author Li, Xiaochong
Hu, Bowen
Zheng, Jiachen
Pan, Zhiyong
Cai, Yuxiang
Zhao, Mingjuan
Jin, Xiaoqing
Li, Zhi-Qiang
author_facet Li, Xiaochong
Hu, Bowen
Zheng, Jiachen
Pan, Zhiyong
Cai, Yuxiang
Zhao, Mingjuan
Jin, Xiaoqing
Li, Zhi-Qiang
author_sort Li, Xiaochong
collection PubMed
description INTRODUCTION: Temozolomide (TMZ) induces intestinal mucosa injury that cannot be fully counteracted by supportive treatment. Probiotics regulate gut microbial composition and the host immune system and may alleviate this side effect. We aimed to investigate the potential and mechanism of Lactobacillus rhamnosus GG (LGG) in relieving intestinal mucosal injury induced by TMZ. METHODS: Glioblastoma mice were divided into four groups: CON (control), LGG (10(9) CFU/mL, treated for 7 days), TMZ (50 mg/kg·d, treated for 5 days), LGG+TMZ (LGG for 7 days and TMZ subsequently for 5 days). Body weight, food intake, and fecal pH were recorded. Intestinal tissue samples were collected 1 day after the end of TMZ treatment. Degree of damage to intestine, expression of IL1β, IL6, TNFα, and IL10 in jejunum were determined. Levels of tight-junction proteins (ZO1, occludin), TLR4, IKKβ, IκBα, and P65 with their phosphorylation in jejunum were measured. RESULTS: Decreases in body weight, food intake, spleen index in the TMZ group were mitigated in the LGG+TMZ group, and the degree of intestinal shortening and damage to jejunum villus were also alleviated. The expression of tight-junction proteins in the LGG+TMZ group was significantly greater than that in the TMZ group. IκBα in intestinal tissue significantly decreased in the TMZ group, phos–IKKβ and phos-P65 increased compared to the CON group, and LGG reversed such changes in IκBα and phos-P65 in the LGG+TMZ group. Intestinal inflammatory cytokines were significantly increased in the TMZ group, but lower in the LGG+TMZ group. Moreover, expression of TLR4 in LGG group was significantly lower than that in the CON group. LGG inhibited the rise of TLR4 after TMZ in the LGG+TMZ group compared to the TMZ group. CONCLUSION: LGG inhibits the activation of the TLR4–NFκB pathway and alleviates intestinal mucosal inflammation induced by TMZ, thereby protect the jejunum villi and mucosal physical barrier.
format Online
Article
Text
id pubmed-10386857
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103868572023-07-30 Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway Li, Xiaochong Hu, Bowen Zheng, Jiachen Pan, Zhiyong Cai, Yuxiang Zhao, Mingjuan Jin, Xiaoqing Li, Zhi-Qiang Drug Des Devel Ther Original Research INTRODUCTION: Temozolomide (TMZ) induces intestinal mucosa injury that cannot be fully counteracted by supportive treatment. Probiotics regulate gut microbial composition and the host immune system and may alleviate this side effect. We aimed to investigate the potential and mechanism of Lactobacillus rhamnosus GG (LGG) in relieving intestinal mucosal injury induced by TMZ. METHODS: Glioblastoma mice were divided into four groups: CON (control), LGG (10(9) CFU/mL, treated for 7 days), TMZ (50 mg/kg·d, treated for 5 days), LGG+TMZ (LGG for 7 days and TMZ subsequently for 5 days). Body weight, food intake, and fecal pH were recorded. Intestinal tissue samples were collected 1 day after the end of TMZ treatment. Degree of damage to intestine, expression of IL1β, IL6, TNFα, and IL10 in jejunum were determined. Levels of tight-junction proteins (ZO1, occludin), TLR4, IKKβ, IκBα, and P65 with their phosphorylation in jejunum were measured. RESULTS: Decreases in body weight, food intake, spleen index in the TMZ group were mitigated in the LGG+TMZ group, and the degree of intestinal shortening and damage to jejunum villus were also alleviated. The expression of tight-junction proteins in the LGG+TMZ group was significantly greater than that in the TMZ group. IκBα in intestinal tissue significantly decreased in the TMZ group, phos–IKKβ and phos-P65 increased compared to the CON group, and LGG reversed such changes in IκBα and phos-P65 in the LGG+TMZ group. Intestinal inflammatory cytokines were significantly increased in the TMZ group, but lower in the LGG+TMZ group. Moreover, expression of TLR4 in LGG group was significantly lower than that in the CON group. LGG inhibited the rise of TLR4 after TMZ in the LGG+TMZ group compared to the TMZ group. CONCLUSION: LGG inhibits the activation of the TLR4–NFκB pathway and alleviates intestinal mucosal inflammation induced by TMZ, thereby protect the jejunum villi and mucosal physical barrier. Dove 2023-07-25 /pmc/articles/PMC10386857/ /pubmed/37521036 http://dx.doi.org/10.2147/DDDT.S403087 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Xiaochong
Hu, Bowen
Zheng, Jiachen
Pan, Zhiyong
Cai, Yuxiang
Zhao, Mingjuan
Jin, Xiaoqing
Li, Zhi-Qiang
Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title_full Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title_fullStr Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title_full_unstemmed Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title_short Probiotics Alleviate Chemotherapy-Associated Intestinal Mucosal Injury via the TLR4–NFκB Signaling Pathway
title_sort probiotics alleviate chemotherapy-associated intestinal mucosal injury via the tlr4–nfκb signaling pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386857/
https://www.ncbi.nlm.nih.gov/pubmed/37521036
http://dx.doi.org/10.2147/DDDT.S403087
work_keys_str_mv AT lixiaochong probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT hubowen probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT zhengjiachen probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT panzhiyong probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT caiyuxiang probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT zhaomingjuan probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT jinxiaoqing probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway
AT lizhiqiang probioticsalleviatechemotherapyassociatedintestinalmucosalinjuryviathetlr4nfkbsignalingpathway